Palisade Bio, Inc. (NASDAQ:PALI – Get Free Report)’s stock price was up 9% during mid-day trading on Friday . The stock traded as high as $4.22 and last traded at $3.89. Approximately 135,870 shares changed hands during trading, a decline of 68% from the average daily volume of 427,719 shares. The stock had previously closed at $3.57.
Palisade Bio Trading Up 9.0 %
The company has a market capitalization of $3.64 million, a P/E ratio of -0.16 and a beta of 1.34. The stock has a 50 day moving average price of $3.59 and a 200 day moving average price of $4.52.
Palisade Bio (NASDAQ:PALI – Get Free Report) last posted its earnings results on Monday, August 12th. The company reported ($3.32) EPS for the quarter. On average, research analysts predict that Palisade Bio, Inc. will post -13.11 EPS for the current year.
About Palisade Bio
Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.
Featured Articles
- Five stocks we like better than Palisade Bio
- What is a Stock Market Index and How Do You Use Them?
- Is Spotify Stock Poised to Soar? Options Traders Think So
- Airline Stocks – Top Airline Stocks to Buy Now
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- How Technical Indicators Can Help You Find Oversold StocksĀ
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.